The OMB Federal Grant Overhaul: What NIH-Funded Medical Researchers Need to Know

If you have an active NIH grant or are preparing an application, the last week of May 2026 brought news that is worth reading carefully. On May 29, the Office of Management and Budget, joined by virtually every federal grantmaking agency, published a proposed rule that would restructure how the federal government distributes research funding. The headline number is 412 pages. The practical effect, if the rule is finalized as written, would be to insert senior political appointees into the grant award process in a way that has no precedent in the post-World War II era of US science funding.

This is a proposed rule, not a final one. The public comment period runs through July 13, 2026, and the OMB has indicated it aims to issue a final rule by October 1 to take effect at the start of fiscal year 2027. A great deal could change between now and then, including the possibility that the rule is significantly narrowed, challenged in court, or delayed. What is certain is that the proposal itself is real, that it is now in the public record, and that medical researchers who will be affected have a defined window to respond.

What the Proposal Actually Says

The OMB proposal is a revision to what is known as the Uniform Guidance, the federal framework that governs how agencies administer grants across all departments. Because NIH, NSF, AHRQ, CDC, and every other federal science funder operate under this framework, a change to the Uniform Guidance affects all of them simultaneously, not just one agency.

The most significant structural change in the proposal is a requirement that all discretionary grant awards undergo a "pre-issuance review" by one or more senior political appointees before the award can be made. The proposal frames this as ensuring alignment with the President's policy priorities. In practice, it means that a grant application could pass scientific peer review at the Center for Scientific Review, receive a fundable score, and then be blocked by a political official who determines that the work does not serve the administration's stated priorities.

The proposal also explicitly states that peer review "remains advisory and does not replace agency discretion." That sentence is a departure from how the US research funding system has operated for decades. Since the creation of the National Science Foundation in 1950 and the expansion of NIH through the 1970s, scientific peer review by independent experts has served as the primary determinant of funding. The proposed rule does not eliminate peer review, but it reframes it as one input among several rather than the governing standard.

The Publication Funding Provision: What It Means for Open Access

For researchers who regularly use NIH grant funds to pay open-access article processing charges, the publication funding restriction deserves particular attention. The proposed rule would restrict federal financial support for the publication of US scientists' results in scientific journals. The precise scope of this restriction is not fully defined in the proposal, and much will depend on how implementing agencies interpret the language.

At minimum, it raises real questions for researchers currently planning publication budgets on active or pending grants. The NIH Public Access Policy already requires that peer-reviewed manuscripts arising from NIH funding be deposited in PubMed Central within 12 months of publication. NIH removed its previous embargo period in July 2025. Whether depositing to PubMed Central would count as "publication support" under the new rule, and whether APC payments would be treated differently from open-access compliance deposits, is not clear from the proposal text.

This comes at an already complicated time for open-access funding. As covered separately in this series, HHMI banned hybrid journal APC payments in January 2026 and Cancer Research UK withdrew all APC funding in April 2026. NIH had separately proposed capping APCs at between $2,000 and $6,000 per paper. If the OMB rule further constrains how grant funds can be used for publication, researchers who assumed they could budget for open-access fees on federal awards may need to identify alternative funding sources or shift their publication strategy toward journals with lower or no APCs.

International Collaboration Restrictions

The proposed rule would also limit collaborations between federally funded US scientists and overseas colleagues. The details here are not fully specified in the proposal, but the direction is consistent with earlier executive actions in 2025 that targeted certain international partnerships, particularly with institutions in China. What the Uniform Guidance revision adds is a broader framework that would apply across all international collaborations funded by federal awards, regardless of the country involved.

For medical researchers, this has practical implications beyond grant administration. Many of the most important large-scale studies in cardiology, oncology, and infectious disease are inherently multinational, because single-country cohorts are often too small to answer the questions that need answering. Multi-site international trials, coordinated registry studies, and global disease surveillance networks all depend on federal grant structures that accommodate overseas partners. If the new rule makes it administratively harder to include overseas investigators as key personnel, it will reshape how those studies are designed before they reach the publication stage.

None of this means that international collaboration would stop. Institutional and private foundations funding would remain available, and researchers would likely shift funding structures accordingly. But the grant-writing and budgeting workflows for any study with overseas sites would become more complicated, and the publication authorship landscape of those studies could change as a result.

The Payline Change and What It Means for Application Strategy

Separate from but related to the OMB proposal, NIH has already ended its payline system. Paylines were the percentile score cutoffs that many NIH institutes used as their primary funding threshold. If your application scored at or below the payline, it was typically funded. If not, it was not. That system had the virtue of transparency: researchers knew what score they needed, and the outcome was largely predictable from the study section score.

Under the new system, all 27 NIH institutes and centers must consider additional factors, including the applicant's career stage, existing funding, geographic location, and the institute's own research priorities. This is a meaningful change for how applicants should think about their applications. A strong study section score is no longer sufficient on its own, and researchers who relied on paylines to calibrate their resubmission decisions now have less information to work with.

The practical implication for publication strategy is indirect but real. If funding becomes more discretionary and less score-based, the typical grant cycle from application to funding to data collection to publication will be harder to project. Researchers who build their publication timelines against anticipated grant funding periods may need to build in more uncertainty than before. That is not a reason to delay, but it is a reason to maintain a realistic buffer between grant-dependent data collection and journal submission.

How the Scientific Community Has Responded

The reaction from researchers and scientific institutions has been, as one would expect, strongly negative. Gregg Gonsalves, an epidemiologist at Yale University's School of Public Health, described the proposal as declaring "war on honest science" in a statement from Defend Public Health. Professional societies including the American Chemical Society and the Association for Clinical and Translational Science have indicated they will submit formal comments. University research offices at institutions including the University of Rochester and others have already circulated internal guidance alerting faculty to the comment period.

The strongest objection is structural rather than political. The argument made by research advocates is not simply that the current administration's priorities are wrong, but that merit-based peer review was specifically designed to insulate scientific funding from the preferences of any particular administration. The US has maintained that system through changes of government on both sides of the aisle for seven decades, and that consistency is itself a source of scientific strength. A rule that makes all funding conditional on the alignment with the President's policy priorities, regardless of which party is in power, creates a mechanism for interference that will remain available to future administrations as well.

Whether those arguments will shift the final rule is uncertain. Legal challenges are also likely, though the timeline for court proceedings would likely extend beyond the proposed October 1 implementation date even if they are filed immediately after a final rule is published.

What This Means for Your Manuscript and Publication Plans

For researchers with papers in progress or in the pipeline, there are several concrete questions worth thinking through now rather than after the rule is finalized.

First, if your work involves areas that have been flagged in recent administration communications, including reproductive health, gender medicine, certain categories of infectious disease research, DEI-related health equity research, and some areas of climate-health research, you should be aware that the expanded suspension and termination authority in the proposed rule would make it easier for an agency to end an active award if it is determined to be outside current priorities. This is a broader risk than APC funding and is worth discussing with your sponsored research officer.

Second, if you are planning publications that will need APC support from an NIH grant, it would be prudent to identify alternatives now rather than waiting for clarification. Transformative agreements negotiated by your institution's library with publishers such as Springer Nature, Wiley, or Elsevier often provide APC-free open access for corresponding authors at subscribing institutions. DOAJ-indexed fully open-access journals do not charge APCs at all, and some of the most respected specialty journals in medicine, including many BMC and PLOS titles, operate on either no-APC or low-APC models.

Third, the preprint requirement from HHMI (effective January 2026) and the broader push toward preprint-first publication from funders are worth reconsidering in this context. Posting a preprint to medRxiv or bioRxiv before journal submission satisfies many funder open-access requirements at no cost, independent of what happens with NIH's APC policies. If the rule restricts journal-publication funding but not preprint server deposits, a preprint-first strategy would effectively decouple open access compliance from APC payment.

How to Submit Comments Before July 13

The 45-day public comment window is unusually short for a rule of this scope and consequence. For context, major federal regulatory changes typically allow 60 to 90 days for comment. The compressed timeline means that if you plan to submit, you should start drafting now rather than in early July.

Comments are submitted through the federal regulations portal at regulations.gov by searching for the OMB Uniform Guidance proposed rule. Professional societies submitting on behalf of their members generally want input from researchers who can speak to specific programmatic impacts. If your institution has a federal relations office or a sponsored research office, those units are likely coordinating institutional comment letters and can tell you whether there is a mechanism to add your voice to a coordinated submission.

A useful comment is specific, not general. It names the section of the proposed rule you are addressing, describes the specific programmatic or operational impact it would have on your work or your institution, and offers a concrete alternative or modification rather than simply opposing the provision. Comments that say peer review should remain determinative are more actionable if they explain which specific language in the proposed rule they are responding to and what the replacement language should say.

Whether any individual comment changes the final rule is impossible to predict. But the administrative record created by the comment period is the factual foundation that courts would use if the rule is challenged, and a thin record weakens the case for legal review. The comment process is not performative. It has practical downstream significance.

The Broader Context for Medical Researchers

The OMB proposal is the most sweeping single action in the federal research funding landscape in 2026, but it sits alongside a series of other changes that have been accumulating over the past 18 months. NIH cancelled over 370 peer review meetings between October and November 2025 due to what it described as a shutdown-related backlog, creating delays in the awards pipeline that are still working their way through the system. Several NIH institutes have been operating under continuing resolutions rather than full appropriations, limiting their flexibility in making new awards. The payline system was ended earlier in 2026. And the broader political scrutiny of topics like health equity, gender medicine, and environmental health has already caused some researchers to adjust how they frame their aims.

None of this means that NIH-funded medical research is ending. The NIH budget, even in a constrained environment, remains by far the largest single source of biomedical research funding in the world. But the predictability and insulation from political pressure that have historically characterized that funding system are genuinely at risk in a way that they have not been in recent memory. Researchers who understand what is being proposed, follow the comment period, and adjust their publication and budget planning accordingly will be in a better position than those who assume the current situation is temporary and will resolve without their attention.

The practical takeaway is not to panic but to plan with more uncertainty than you have in previous grant cycles. Comment before July 13. Map your publication budget to alternatives that do not depend on NIH APC support. Talk to your sponsored research office about how your active awards might be affected by expanded suspension authority. And keep an eye on what institutions, professional societies, and legal advocates do with their own comments, because the final rule, whenever it appears, will reflect what that record contains.

Further Reading